Core Insights - BioRestorative Therapies, Inc. has appointed Sandy Lipkins as a leader in technology commercialization and business development, effective June 9, 2025, to enhance strategic alliances and licensing agreements [1][2][3] Company Overview - BioRestorative Therapies focuses on regenerative medicine, particularly stem cell-based therapies, with two main clinical development programs targeting disc/spine disease and metabolic disorders [5] - The company operates a commercial BioCosmeceutical platform, which includes a cell-based secretome product designed to reduce fine lines and wrinkles [7] Leadership Background - Sandy Lipkins brings over 30 years of experience in venture capital, finance, and sales, with a strong focus on anti-aging and wellness sectors, and has a proven track record in scaling companies and expanding market reach [2][3] - His expertise in stem cells and regenerative medicine is expected to drive significant value creation for BioRestorative as it advances its clinical pipeline and commercial offerings [3][4] Clinical Development Programs - The Disc/Spine Program includes BRTX-100, a cell therapy candidate for treating painful lumbosacral disc disorders, currently in Phase 2 clinical trials [5] - The Metabolic Program, ThermoStem, aims to develop therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [6] Future Aspirations - The company aims to accelerate growth and expand its BioCosmeceuticals platform under Lipkins' leadership, with a focus on bringing transformative regenerative solutions to both domestic and international markets [4][3]

Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs [2] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [2] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [2] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [2] - The HLHS program has received three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [2] - The Alzheimer's disease program has received two FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [2] Upcoming Events - Wa'el Hashad, CEO of Longeveron, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 16-17, 2025 [1] - The conference presentation will be accessible via a webcast, with a replay available on the company's website for 90 days following the event [1]

Core Viewpoint - NurExone Biologic Inc. is advancing its exosome-based therapy platform, particularly focusing on its lead candidate ExoPTEN, which targets high-impact neurological conditions. The company is also seeking shareholder approval for its amended Omnibus Plan at an upcoming meeting [1][6]. Manufacturing Process and Clinical Readiness - The company presented promising early data on the viability and potency of cells from its proprietary Master Cell Bank (MCB) at a recent conference, indicating strong economic potential for exosome production [2][3]. - The MCB is crucial for establishing GMP-compliant manufacturing processes for exosomes, which are intended to support clinical trials and future commercial supply [3][4]. - NurExone plans to transfer its manufacturing process to its U.S.-based subsidiary, Exo-Top, to enhance clinical readiness and scalability [3][4]. Product Development and Market Potential - ExoPTEN is being developed as a first-in-class therapy for conditions such as acute spinal cord injury and optic nerve damage, which represent multi-billion-dollar markets [4][9]. - The company expects to initiate its first human clinical trial for ExoPTEN in 2026, continuing to expand its manufacturing capabilities for exosome-based regenerative therapies [5][9]. Omnibus Plan and Shareholder Approval - At the upcoming meeting, shareholders will consider the amended Omnibus Plan, which includes housekeeping amendments that do not affect securityholder rights [6][7]. - The maximum number of common shares reserved for RSUs and Restricted Shares is fixed at 10% of the issued and outstanding shares, currently anticipated to be 7,800,791 [8].

Core Viewpoint - Sernova Biotherapeutics is making significant progress in its mission to develop a functional cure for type 1 diabetes (T1D) through its innovative Cell Pouch Bio-hybrid Organ technology, while also undergoing leadership changes and pursuing financing opportunities [1][3]. Company Developments - Jonathan Rigby has been appointed as Interim Chair of the board of directors, effective immediately, while the company searches for a new independent director to take on the Chair role [1]. - The company is actively engaged in financing discussions with GoldTrack Ventures and the Kingdom of Saudi Arabia, which are seen as promising partnerships [2]. - Sernova has released encouraging clinical data and formed a Clinical Advisory Board, indicating progress in its strategic and operational initiatives [3]. - The departure of Modestus Obochi, the Chief Business Officer, has been announced, with the company expressing gratitude for his contributions [3]. Technology and Innovation - Sernova is focused on developing regenerative medicine therapeutics that combine its Cell Pouch with human donor cells or stem-cell derived islet-like clusters, in collaboration with Evotec, to create Bio-hybrid Organs aimed at treating T1D and thyroid disorders [4].

Core Insights - Celularity Inc. has developed a proprietary advanced biomaterial technology, specifically a tri-layer decellularized, dehydrated human amniotic membrane (DDHAM-3L), which serves as a novel cellular delivery system for ocular surface reconstruction [1][2][4] - The research published in the journal Regenerative Engineering and Translational Medicine highlights the potential of DDHAM-3L in supporting the proliferation and stemness of induced pluripotent stem cell (iPSC)-derived limbal stem cells (LSCs) for treating limbal stem cell deficiency (LSCD) and other ocular surface disorders [2][3] - The study indicates that iPSC-LSCs seeded on DDHAM-3L formed confluent cell sheets and exhibited a higher proliferation rate compared to controls, demonstrating its effectiveness as an advanced biomaterial [3][4] Company Overview - Celularity Inc. is focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies, leveraging the unique biology of the postpartum placenta to address unmet global healthcare needs [5] - The company aims to advance its DDHAM-3L technology for broader clinical applications beyond ophthalmology, emphasizing its scalability and patient-specific benefits [4][5]

Company Overview - Healios K.K. is Japan's leading clinical stage biotechnology company focused on regenerative medicine using stem cells [3] - The company was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 under the TSE Growth Code 4593 [3] Product Development - Healios is developing a proprietary cell product called invimestrocel (HLCM051), which consists of multipotent adult progenitor cells (MAPCs) derived from the bone marrow of healthy adult donors [3] - The company is advancing invimestrocel for indications including ischemic stroke, acute respiratory distress syndrome (ARDS), and trauma [3] - Healios has confirmed its path to conditional approval in Japan for the use of invimestrocel for ARDS and is preparing to file for approval and commercial launch [3] Upcoming Events - Richard Kincaid, Chief Financial Officer of Healios, will present at the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 2:35 PM Eastern Standard Time [1] - A live and archived webcast of the presentation will be accessible from Jefferies' website, with a replay available for 60 days [2]

Core Insights - Sernova Biotherapeutics has formed a Clinical Advisory Board to guide the development of its Cell Pouch Bio-hybrid Organ as a potential functional cure for type 1 diabetes (T1D) [1][7] Group 1: Clinical Advisory Board Composition - The board consists of five members, chaired by Dr. Robert Gabbay, who has extensive experience in diabetes care and research [2] - Other notable members include: - Dr. Mark Atkinson, a leading researcher in T1D with over 750 publications [3] - Dr. Melena Bellin, an expert in islet cell transplantation for T1D [4] - Dr. Andrew Posselt, a surgeon-scientist specializing in transplant immunology [5] - Dr. Holger Russ, who focuses on regenerative medicine and autoimmune type 1 diabetes [6] Group 2: Company Overview and Technology - Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics, specifically the Cell Pouch integrated with human donor cells or stem-cell derived islet-like clusters [8] - The Cell Pouch is designed to create bio-hybrid organs that restore or enhance organ function, initially targeting T1D and thyroid disorders [9]

Core Viewpoint - Longeveron Inc. is actively pursuing partnerships for its Alzheimer's disease program, which has shown promising results in clinical trials, particularly with its lead candidate, laromestrocel [2][5]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with laromestrocel as its lead investigational product [7]. - Laromestrocel is an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors, with potential applications across various disease areas [7]. Clinical Trial Results - The Phase 2a clinical trial (CLEAR MIND) demonstrated that laromestrocel treated patients experienced an overall slowing or prevention of disease worsening compared to placebo, achieving primary safety and secondary efficacy endpoints [3][4]. - Statistically significant improvements were observed in pre-specified clinical and biomarker endpoints for specific laromestrocel groups compared to placebo [3]. Regulatory Designations - The FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer's disease, facilitating greater access to FDA interactions during its development [5]. - Laromestrocel is noted as the first cellular therapeutic candidate to receive FDA RMAT designation for Alzheimer's disease [5]. Upcoming Events - Longeveron will participate in the BIO International Convention from June 16-19, 2025, to explore potential partnerships and strategic opportunities for its Alzheimer's disease program [1][2].

As filed with the Securities and Exchange Commission on May 19, 2025. Registration No. 333-285692 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REGENTIS BIOMATERIALS LTD. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organizat ...

Core Insights - Sernova Biotherapeutics announced positive interim data from its Phase 1/2 clinical trial for its Cell Pouch Bio-hybrid Organ aimed at treating type 1 diabetes (T1D) [1][2] Group 1: Clinical Trial Results - Interim data from 12 patients show that 8 achieved insulin independence, with islet cell engraftment and improved glycemic control [2][3] - 7 out of 12 patients demonstrated C-peptide levels of 0.3 ng/mL or greater, indicating successful islet cell engraftment [4] - 9 of 12 patients had HbA1c levels below the ADA recommended threshold of <7.0%, with one patient showing a 24% reduction in HbA1c from 10.3% to 7.8% [5] Group 2: Patient Quality of Life Improvements - 11 of 12 patients reported improved awareness of hypoglycemia and increased sensitivity to severe hypoglycemic symptoms [7] - 10 of 12 patients showed a reduction in fear of hypoglycemia as measured by the Hypoglycemia Fear Survey-II [8] - 10 of 12 patients experienced a decrease in diabetes distress, indicating improved emotional well-being related to managing T1D [9] Group 3: Future Developments - Clinical trials with iPSC islet-like clusters from Evotec are expected to begin in 2026 after the completion of Cohort C [3] - The study is on track to meet its primary and secondary endpoints, with Cohort C anticipated to initiate in the second half of 2025 [2][10] - The Cell Pouch Bio-hybrid Organ is positioned as a potential functional cure for T1D, combining human donor cells or stem-cell derived islet-like clusters [11]